Cargando…

P650: EFFECTIVENESS OF VENETOCLAX ACCORDING TO THE CHARACTERISTICS OF PATIENTS WITH CLL IN MONOTHERAPY AND COMBINATION WITH RITUXIMAB. INTERIM ANALYSIS OF REAL-LIFE DATA FROM VERONE STUDY

Detalles Bibliográficos
Autores principales:	Ysebaert, Loïc, Troussard, Xavier, Levy, Vincent, Le Calloch, Ronan, Guieze, Romain, Laribi, Kamel, Lepretre, Stephane, Sophie Michallet, Anne, Leblond, Véronique, Feugier, Pierre, Lahjibi, Elhem, Ramier, Julien, Delmer, Alain
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428834/ http://dx.doi.org/10.1097/01.HS9.0000969504.57824.4e

Ejemplares similares

Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO)
por: Quinquenel, Anne, et al.
Publicado: (2020)

Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL
por: D’Rozario, James, et al.
Publicado: (2019)

Veronal Rashes
Publicado: (1908)

PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS)
por: Mato, A. R., et al.
Publicado: (2022)

The Toxic Effects of Veronal
Publicado: (1907)

Veronal in the Vomiting of Pregnancy
por: Reich, A., et al.
Publicado: (1910)

Nervous and Mental Reactions to Veronal: With Report of a Case of Chronic Veronal Poisoning
Publicado: (1930)

A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial
por: Michallet, Anne-Sophie, et al.
Publicado: (2023)

Veronal: A New Hypnotic
Publicado: (1904)

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
por: Seymour, John F., et al.
Publicado: (2022)

Review of Venetoclax in CLL, AML and Multiple Myeloma
por: Lasica, Masa, et al.
Publicado: (2021)

La obra pictórica completa de Veronés
Publicado: (1976)

A Readily Soluble Hypnotic of the Veronal Group
Publicado: (1908)

Drug Reactions from Barbital (Veronal) and Phenobarbital (Luminal)
por: Poole, Allan K.
Publicado: (1929)

Venetoclax: A Novel Therapeutic Agent for CLL with CNS Involvement
por: Karbhari, Nishika, et al.
Publicado: (2022)

Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups
por: Gagez, A-L, et al.
Publicado: (2016)

Progressive Multifocal Leukoencephalopathy in B-CLL Successfully Treated With Venetoclax and Pembrolizumab
por: Olivieri, Jacopo, et al.
Publicado: (2022)

Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia
por: Cornet, Edouard, et al.
Publicado: (2014)

Venetoclax-Rituximab Treatment of Relapsed/Refractory CLL During the COVID-19 Pandemic: A Real-Life Experience in Selected Central-Southern Italian Regions
por: Molica, Stefano, et al.
Publicado: (2021)

CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report
por: Baumann, Tycho, et al.
Publicado: (2020)

COVID-19 among fit patients with CLL treated with venetoclax-based combinations
por: Fürstenau, Moritz, et al.
Publicado: (2020)

Humoral Response to mRNA Vaccines BNT162b2 and mRNA-1273 COVID-19 in Chronic Lymphocytic Leukemia Patients
por: Bagacean, Cristina, et al.
Publicado: (2021)

Humoral response to mRNA anti–COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia
por: Bagacean, Cristina, et al.
Publicado: (2022)

ITCA 650
por: Bertsch, Taylor, et al.
Publicado: (2018)

Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication
por: Lu, Pin, et al.
Publicado: (2021)

Can Treatment with Venetoclax for Chronic Lymphocytic Leukemia (CLL) Result In Autoimmune Hemolytic Anemia?
por: Abdel-Samad, Nizar, et al.
Publicado: (2021)

Idelalisib or Placebo in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL - Interim Results of a Phase 3 Randomized, Double-blind Placebo-Controlled Trial
por: Zelenetz, Andrew D., et al.
Publicado: (2017)

Venetoclax with high‐dose methotrexate and rituximab seem effective and well‐tolerated in the treatment of central nervous system involvement of chronic lymphocytic leukemia: A case report
por: Beziat, Guillaume, et al.
Publicado: (2020)

Prevalence of gastrointestinal parasites in children from Verón, a rural city of the Dominican Republic
por: Childers, Kristin A Geers, et al.
Publicado: (2014)

S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL)
por: Kater, Arnon, et al.
Publicado: (2023)

Rituximab mechanisms of action in B-CLL: a new piece of the puzzle
por: Watier, Hervé
Publicado: (2018)

PB1925: NAOS STUDY: FIRST INTERIM ANALYSIS OF ACALABRUTINIB USE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN A REAL-LIFE SETTING.
por: Quinquenel, Anne, et al.
Publicado: (2023)

Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study
por: Michallet, Anne-Sophie, et al.
Publicado: (2018)

Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4 T cells
por: van Bruggen, J. A. C., et al.
Publicado: (2022)

Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy
por: Thijssen, Rachel, et al.
Publicado: (2022)

Case Report: Rapid renal response to venetoclax monotherapy in a CLL patient with secondary membranous glomerulonephritis
por: Lovato, Ester, et al.
Publicado: (2023)

Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study
por: Egle, Alexander, et al.
Publicado: (2018)

BEBC: 650 000 expansions
Publicado: (1975)

P619: TRACKING DISEASE PARAMETERS BY MRD, CT AND PET IN FIRST LINE CLL PATIENTS TREATED WITH FIXED DURATION IBRUTINIB-VENETOCLAX; INTERIM ANALYSIS OF THE FIRST 30 PATIENTS IN HOVON 158/NEXT STEP TRIAL.
por: Kersting, Sabina, et al.
Publicado: (2023)

PB2353: HEALTHCARE RESOURCE UTILIZATION AND COSTS OFF THERAPY WITH FIXED-DURATION VENETOCLAX AMONG CLL PATIENTS
por: Allan, J. N., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5eue2mqb320dgufll46n9tgpor